These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

244 related articles for article (PubMed ID: 11034390)

  • 1. Structure-guided identification of C3d residues essential for its binding to complement receptor 2 (CD21).
    Clemenza L; Isenman DE
    J Immunol; 2000 Oct; 165(7):3839-48. PubMed ID: 11034390
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Isolating the Epstein-Barr virus gp350/220 binding site on complement receptor type 2 (CR2/CD21).
    Young KA; Chen XS; Holers VM; Hannan JP
    J Biol Chem; 2007 Dec; 282(50):36614-25. PubMed ID: 17925391
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mutational analysis of the complement receptor type 2 (CR2/CD21)-C3d interaction reveals a putative charged SCR1 binding site for C3d.
    Hannan JP; Young KA; Guthridge JM; Asokan R; Szakonyi G; Chen XS; Holers VM
    J Mol Biol; 2005 Feb; 346(3):845-58. PubMed ID: 15713467
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mutational analyses reveal that the staphylococcal immune evasion molecule Sbi and complement receptor 2 (CR2) share overlapping contact residues on C3d: implications for the controversy regarding the CR2/C3d cocrystal structure.
    Isenman DE; Leung E; Mackay JD; Bagby S; van den Elsen JM
    J Immunol; 2010 Feb; 184(4):1946-55. PubMed ID: 20083651
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Delineation of the complement receptor type 2-C3d complex by site-directed mutagenesis and molecular docking.
    Shaw CD; Storek MJ; Young KA; Kovacs JM; Thurman JM; Holers VM; Hannan JP
    J Mol Biol; 2010 Dec; 404(4):697-710. PubMed ID: 20951140
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Molecular dynamics simulations of wild type and mutants of human complement receptor 2 complexed with C3d.
    Wan H; Hu JP; Tian XH; Chang S
    Phys Chem Chem Phys; 2013 Jan; 15(4):1241-51. PubMed ID: 23229122
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mutation of residues in the C3dg region of human complement component C3 corresponding to a proposed binding site for complement receptor type 2 (CR2, CD21) does not abolish binding of iC3b or C3dg to CR2.
    Diefenbach RJ; Isenman DE
    J Immunol; 1995 Mar; 154(5):2303-20. PubMed ID: 7868901
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Structural studies in solution of the recombinant N-terminal pair of short consensus/complement repeat domains of complement receptor type 2 (CR2/CD21) and interactions with its ligand C3dg.
    Guthridge JM; Rakstang JK; Young KA; Hinshelwood J; Aslam M; Robertson A; Gipson MG; Sarrias MR; Moore WT; Meagher M; Karp D; Lambris JD; Perkins SJ; Holers VM
    Biochemistry; 2001 May; 40(20):5931-41. PubMed ID: 11352728
    [TBL] [Abstract][Full Text] [Related]  

  • 9. C3d adjuvant activity is reduced by altering residues involved in the electronegative binding of C3d to CR2.
    Toapanta FR; DeAlmeida DR; Dunn MD; Ross TM
    Immunol Lett; 2010 Mar; 129(1):32-8. PubMed ID: 20064559
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Kinetic analysis of the interactions of complement receptor 2 (CR2, CD21) with its ligands C3d, iC3b, and the EBV glycoprotein gp350/220.
    Sarrias MR; Franchini S; Canziani G; Argyropoulos E; Moore WT; Sahu A; Lambris JD
    J Immunol; 2001 Aug; 167(3):1490-9. PubMed ID: 11466369
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Epitope mapping using the X-ray crystallographic structure of complement receptor type 2 (CR2)/CD21: identification of a highly inhibitory monoclonal antibody that directly recognizes the CR2-C3d interface.
    Guthridge JM; Young K; Gipson MG; Sarrias MR; Szakonyi G; Chen XS; Malaspina A; Donoghue E; James JA; Lambris JD; Moir SA; Perkins SJ; Holers VM
    J Immunol; 2001 Nov; 167(10):5758-66. PubMed ID: 11698449
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The electrostatic nature of C3d-complement receptor 2 association.
    Morikis D; Lambris JD
    J Immunol; 2004 Jun; 172(12):7537-47. PubMed ID: 15187133
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mapping of the C3d ligand binding site on complement receptor 2 (CR2/CD21) using nuclear magnetic resonance and chemical shift analysis.
    Kovacs JM; Hannan JP; Eisenmesser EZ; Holers VM
    J Biol Chem; 2009 Apr; 284(14):9513-20. PubMed ID: 19164292
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Generation of three different fragments of bound C3 with purified factor I or serum. II. Location of binding sites in the C3 fragments for factors B and H, complement receptors, and bovine conglutinin.
    Ross GD; Newman SL; Lambris JD; Devery-Pocius JE; Cain JA; Lachmann PJ
    J Exp Med; 1983 Aug; 158(2):334-52. PubMed ID: 6224880
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Electrostatic Steering Accelerates C3d:CR2 Association.
    Mohan RR; Huber GA; Morikis D
    J Phys Chem B; 2016 Aug; 120(33):8416-23. PubMed ID: 27092816
    [TBL] [Abstract][Full Text] [Related]  

  • 16. X-ray crystal structure of C3d: a C3 fragment and ligand for complement receptor 2.
    Nagar B; Jones RG; Diefenbach RJ; Isenman DE; Rini JM
    Science; 1998 May; 280(5367):1277-81. PubMed ID: 9596584
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Solution structure of the complex between CR2 SCR 1-2 and C3d of human complement: an X-ray scattering and sedimentation modelling study.
    Gilbert HE; Eaton JT; Hannan JP; Holers VM; Perkins SJ
    J Mol Biol; 2005 Feb; 346(3):859-73. PubMed ID: 15713468
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Structure of complement receptor 2 in complex with its C3d ligand.
    Szakonyi G; Guthridge JM; Li D; Young K; Holers VM; Chen XS
    Science; 2001 Jun; 292(5522):1725-8. PubMed ID: 11387479
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A crystal structure of the complex between human complement receptor 2 and its ligand C3d.
    van den Elsen JM; Isenman DE
    Science; 2011 Apr; 332(6029):608-11. PubMed ID: 21527715
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A theoretical view of the C3d:CR2 binding controversy.
    Mohan RR; Gorham RD; Morikis D
    Mol Immunol; 2015 Mar; 64(1):112-22. PubMed ID: 25433434
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.